**Author details**

Navdeep Singh Sidhu1 \* and Sumandeep Kaur2

1 Department of Cardiology, GGS Medical College and Baba Farid University of Health Sciences, Faridkot, Punjab, India

2 Faculty of Nursing Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India

\*Address all correspondence to: navsids@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Thrombolytic Therapy in Pulmonary Thromboembolism DOI: http://dx.doi.org/10.5772/intechopen.100600*

### **References**

[1] Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;**34**:23632371

[2] Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circulation Research. 2016;**118**:13401347

[3] Keller K, Hobohm L, Ebner M, Kresoja KP, Munzel T, Konstantinides SV, et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal. 2020;**41**:522529

[4] Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Archives of Internal Medicine. 2011;**171**:831

[5] Konstantinides SV. Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news? Thrombosis and Haemostasis. 2016;**115**:233

[6] Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979- 1998: an analysis using multiple-cause mortality data. Archives of Internal Medicine. 2003;**163**:1711

[7] Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis. 2007 Apr;**5**(4):692-699. DOI: 10.1111/j.1538-7836.2007.02450.x

[8] Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a

real-world population: the Q-VTE Study Cohort. Am J Med 2013; 126:832.e13

[9] Lassila R, Jula A, Pitkäniemi J, Haukka J. The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open 2014; 4:e005862

[10] Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis 2007;98:756764

[11] de Miguel-Diez J, Jimenez-Garcia R, Jimenez D, Monreal M, Guijarro R, Otero R, et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. The European Respiratory Journal. 2014;**44**:942950

[12] Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thrombosis and Haemostasis. 2016;**115**:399405

[13] Lehnert P, Lange T, Moller CH, Olsen PS, Carlsen J. Acute pulmonary embolism in a national Danish cohort: increasing incidence and decreasing mortality. Thrombosis and Haemostasis. 2018;**118**:539546

[14] Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R. Barba R, et al. RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. J Am Coll Cardiol. 2016;**67**: 162170

[15] Agarwal S, Clark D III, Sud K, Jaber WA, Cho L, Menon V. Gender disparities in outcomes and resource utilization for acute pulmonary embolism hospitalizations in the United States. The American Journal of Cardiology. 2015;**116**:12701276

[16] Roy PM, Meyer G, Vielle B, Le Gall C, Verschuren F. Carpentier F, et al. EMDEPU Study Group. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med. 2006;**144**:157164

[17] Jimenez D, Bikdeli B, Barrios D, Morillo R, Nieto R. Guerassimova I, et al. RIETE Investigators. Management appropriateness and outcomes of patients with acute pulmonary embolism. Eur Respir J. 2018;**51**:1800445

[18] Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association [published corrections appear in Circulation. 2012;125:e496 and Circulation. 2012;126:e495]. Circulation. 2011;123:1788-1830. doi: 10.1161/CIR.0b013e318214914f

[19] Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European

Respiratory Society (ERS). European Heart Journal. 2020 Jan 21;**41**(4): 543-603. DOI: 10.1093/eurheartj/ehz405

[20] Vanni S, Nazerian P, Pepe G, Baioni M, Risso M, Grifoni G, et al. Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. Journal of Thrombosis and Haemostasis. 2011;**9**:1916-1923. DOI: 10.1111/j.1538-7836.2011.04459.x

[21] Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of allcause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. Journal of the American Medical Association. 2014;**311**:2414-2421. DOI: 10.1001/jama.2014.5990

[22] Becattini C, Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost. 2008;100:747-751. 20

[23] Lin BW, Schreiber DH, Liu G, Briese B, Hiestand B, Slattery D, et al. Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry. The American Journal of Emergency Medicine. 2012;**30**:1774-1781. DOI: 10.1016/j.ajem.2012.02.012

[24] Secemsky E, Chang Y, Jain CC, Beckman JA, Giri J, Jaff MR, et al. Contemporary management and outcomes of patients with massive and submassive pulmonary embolism. Am J Med. 2018;131:1506-1514.e0. doi: 10.1016/j.amjmed.2018.07.035

[25] Jiménez D, Kopecna D, Tapson V, Briese B, Schreiber D, Lobo JL. et al; PROTECT Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic

*Thrombolytic Therapy in Pulmonary Thromboembolism DOI: http://dx.doi.org/10.5772/intechopen.100600*

pulmonary embolism. American Journal of Respiratory and Critical Care Medicine. 2014;**189**:718-726. DOI: 10.1164/rccm.201311-2040OC

[26] Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thrombosis Research. 2010 Mar;**125**(3):e82-e86. DOI: 10.1016/j. thromres.2009.09.017

[27] Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology. 1992 Sep;**20**(3):520-526. DOI: 10.1016/0735-1097(92)90002-5

[28] Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;**149**(2):315-352. DOI: 10.1016/j. chest.2015.11.026

[29] Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances. 2020 Oct 13;**4**(19):4693-4738. DOI: 10.1182/ bloodadvances.2020001830

[30] Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes GM, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. Journal of Thrombosis and Thrombolysis. 1995;**2**(3):227-229. DOI: 10.1007/BF01062714

[31] Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J. et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. The New England Journal of Medicine. 2014 Apr 10;**370**(15):1402- 1411. DOI: 10.1056/NEJMoa1302097

[32] Konstantinides S, Geibel A, Heusel G, Heinrich F. Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. The New England Journal of Medicine. 2002 Oct 10;**347**(15):1143-1150. DOI: 10.1056/NEJMoa021274

[33] Sharifi M, Bay C, Skrocki L, Rahimi F. Mehdipour M; "MOPETT" Investigators. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). The American Journal of Cardiology. 2013 Jan 15;**111**(2):273-277. DOI: 10.1016/j. amjcard.2012.09.027

[34] Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebocontrolled randomized trial. Journal of Thrombosis and Haemostasis. 2014 Apr;**12**(4):459-468. DOI: 10.1111/ jth.12521

[35] Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2021 Apr 15;4(4):CD004437. doi: 10.1002/14651858.CD004437

[36] Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L. et al; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen

activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010 Feb;**137**(2):254-262. DOI: 10.1378/chest.09-0765

[37] Zhang LY, Gao BA, Jin Z, Xiang GM, Gong Z, Zhang TT, et al. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism. Saudi Med J. 2018 Nov;39(11):1090-1095. doi: 10.15537/ smj.2018.11.22717

[38] Yilmaz ES, Uzun O. Low-dose thrombolysis for submassive pulmonary embolism. J Investig Med. 2021 Jun 7:jim-2021-001816. doi: 10.1136/ jim-2021-001816

[39] Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Oct;**76**(10):970-979. DOI: 10.1136/ thoraxjnl-2020-215383

[40] Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, et al. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Annals of Intensive Care. 2020 Sep 16;**10**:124. DOI: 10.1186/s13613-020-00741-0

[41] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-ofthe-Art Review. Journal of the American College of Cardiology. 2020 Jun 16;**75**(23):2950-2973. DOI: 10.1016/j. jacc.2020.04.031

[42] Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica Chimica Acta. 2020;**506**: 145-148. DOI: 10.1016/j.cca.2020.03.022

[43] Roncon L, Zuin M, Zonzin P. Fibrinolysis in COVID-19 patients with hemodynamic unstable acute pulmonary embolism: yes or no? Journal of Thrombosis and Thrombolysis. 2020;**50**:221-222. DOI: 10.1007/ s11239-020-02131-6
